Quick Answer
Bicara Therapeutics Inc. reported Stockholders Equity of $401.45 million for fiscal year 2025.
Bicara Therapeutics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $401.45M | -18.4% |
| 2024 | $491.88M | +430.6% |
| 2023 | -$148.77M | -50.6% |
| 2022 | -$98.80M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $402.78M | -21.0% | -7.4% |
| June 30, 2025 | $435.20M | +349.0% | -5.2% |
| March 31, 2025 | $458.96M | +386.7% | -6.7% |
| December 31, 2024 | $491.88M | +430.6% | -3.5% |
| September 30, 2024 | $509.56M | +471.6% | +391.5% |
| June 30, 2024 | -$174.78M | -52.2% | -9.2% |
| March 31, 2024 | -$160.08M | -51.2% | -7.6% |
| December 31, 2023 | -$148.77M | -50.6% | -8.5% |
- Bicara Therapeutics Inc. showed a decrease of -18.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Bicara Therapeutics Inc.’s stockholders equity has grown by 506.3% (from -$98.80 million to $401.45 million).
- The most recent figure is from Bicara Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: